2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
Ein Dokument
mehr
Storys zum Thema Medizinische Behandlung
- 2
Record financing rounds at the Munich biotech hub
Ein Dokumentmehr canSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 DokumentemehrPress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
Ein DokumentmehrPress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Ein DokumentmehrcanSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr Leipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
Ein Dokumentmehr- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
Ein Dokumentmehr - 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
Ein Dokumentmehr- 5
Press Release - hubergroup India expands its support for rural healthcare
Ein Dokumentmehr Free Access to Cancer Research Services - canSERV 1st Call for Proposals
Ein DokumentmehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein Dokumentmehr- 2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokumentmehr - 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
Ein DokumentmehrThe development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB
Ein DokumentmehrHigh investor density at the Pitch Day hosted by IZB
Ein Dokumentmehr
1